Vanguard Group Inc. Has $34.42 Million Holdings in Enfusion, Inc. (NYSE:ENFN)

Vanguard Group Inc. decreased its stake in Enfusion, Inc. (NYSE:ENFN) by 16.8% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 3,341,561 shares of the company’s stock after selling 676,290 shares during the quarter. Vanguard Group Inc.’s holdings in Enfusion were worth $34,418,000 at the end of the most recent quarter.

A number of other large investors have also recently bought and sold shares of ENFN. KLP Kapitalforvaltning AS bought a new position in shares of Enfusion during the fourth quarter valued at $75,000. Quantbot Technologies LP bought a new position in Enfusion during the 4th quarter valued at about $144,000. Intech Investment Management LLC acquired a new position in Enfusion in the fourth quarter valued at about $191,000. Fox Run Management L.L.C. bought a new stake in Enfusion during the fourth quarter worth about $265,000. Finally, Rhumbline Advisers grew its stake in Enfusion by 3.0% during the fourth quarter. Rhumbline Advisers now owns 62,464 shares of the company’s stock worth $643,000 after buying an additional 1,796 shares during the last quarter. 81.05% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of research analysts have recently issued reports on ENFN shares. William Blair reiterated a “market perform” rating on shares of Enfusion in a research note on Monday, January 13th. Stifel Nicolaus boosted their price objective on Enfusion from $11.00 to $13.00 and gave the stock a “buy” rating in a research note on Wednesday, December 18th. Finally, Piper Sandler increased their target price on Enfusion from $10.00 to $11.50 and gave the stock a “neutral” rating in a report on Monday, December 23rd.

Enfusion Trading Up 0.1 %

Shares of ENFN stock opened at $10.81 on Monday. Enfusion, Inc. has a 1 year low of $7.83 and a 1 year high of $11.80. The firm’s 50 day moving average is $11.11 and its 200-day moving average is $10.37. The firm has a market capitalization of $1.39 billion, a price-to-earnings ratio of 270.19, a PEG ratio of 1.85 and a beta of 0.92.

Enfusion (NYSE:ENFN) last posted its quarterly earnings data on Monday, March 3rd. The company reported $0.01 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.03 by ($0.02). The firm had revenue of $52.94 million for the quarter, compared to analyst estimates of $53.98 million. Enfusion had a return on equity of 6.67% and a net margin of 1.70%. On average, equities research analysts forecast that Enfusion, Inc. will post 0.06 earnings per share for the current fiscal year.

Insider Activity

In other Enfusion news, CFO Bradley Herring sold 4,645 shares of Enfusion stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $11.38, for a total transaction of $52,860.10. Following the completion of the sale, the chief financial officer now owns 324,689 shares of the company’s stock, valued at approximately $3,694,960.82. The trade was a 1.41 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Oleg Movchan sold 2,790 shares of the stock in a transaction on Monday, March 3rd. The shares were sold at an average price of $11.48, for a total value of $32,029.20. Following the completion of the transaction, the chief executive officer now directly owns 643,299 shares in the company, valued at approximately $7,385,072.52. This trade represents a 0.43 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 66,223 shares of company stock valued at $754,778 over the last 90 days. 36.44% of the stock is owned by company insiders.

About Enfusion

Enfusion, Inc provides software-as-a-service solutions for investment management industry in the United States, Europe, the Middle East, Africa, and the Asia Pacific. The company provides Portfolio Management System, which generates a real-time investment book of record that consists of valuation and risk tools, which allows users to analyze aggregated or decomposed portfolio data for chief investment officers (CIOs) and portfolio managers; and Order and Execution Management System that enables portfolio managers, traders, compliance teams, and analysts to electronically communicate trade orders for a variety of asset classes, manage trade orders, and systemically enforce trading regulations and internal guidelines.